The standard maintenance dose for weight loss is 2.4 mg weekly
The FDA has documented reports of adverse events tied to compounded semaglutide and tirzepatide, some requiring hospitalization, with many traced to dosing errors when patients measured doses from multidose vials
Liraglutide use in patients who have regained weight after bariatric surgery: the first Australian experience
Its origin story is unusual and worth understanding, because the circumstances of its discovery shaped and arguably oversold everything that followed
Bunck, M.D., Ph.D., and Adam Stefanski, M.D., Ph.D., for the SURMOUNT-1 Investigators* Relevant Literature SURMOUNT-1 Trial Relevant Guidelines -SURMOUNT-1 Trial Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guidelines (2015) Drugs may amplify adherence to behavior change and improve physical functioning such that increased physical activity is easier for those who cannot exercise initially